1. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome / H. J. Teede [et al.] // Human Reproduction. - 2023. - № 9 (38). - P. 1655–1679.
2. Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE); Androgen Excess and PCOS Society. American Association of Clinical Endocrinologists, American College Of Endocrinology, And Androgen Excess and Pcos Society Disease State Clinical Review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome - part 2. Endocr Pract. 2015 Dec;21(12):1415-26.
3. Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis / V. Wekker [et al.] // Human reproduction update. - 2020. - № 6 (26). - P. 942–960.
4. Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, et al. Polycysticovarysyndrome. NatureReviewsDiseasePrimers 2016;2:16057.
5. Neven ACH, Laven J, Teede HJ, Boyle JA. A Summary on Polycystic Ovary Syndrome: Diagnostic Criteria, Prevalence, Clinical Manifestations, and Management According to the Latest International Guidelines. Semin Reprod Med. 2018;36(1):5-12.
6. Carmina E, Guastella E, Longo RA. Advances in the Diagnosis and Treatment of PCOS. Curr Pharm Des. 2016;22(36):5508-5514.
7. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41-7.
8. Spritzer PM, Marchesan LB, Santos BR, Fighera TM. Hirsutism, Normal Androgens and Diagnosis of PCOS. Diagnostics (Basel). 2022 Aug 9;12(8):1922. doi: 10.3390/diagnostics12081922.
9. Ezeh U, Huang A, Landay M, Azziz R. Long-Term Response of Hirsutism and Other Hyperandrogenic Symptoms to Combination Therapy in Polycystic Ovary Syndrome. J Womens Health (Larchmt). 2018 Jul;27(7):892-902.
10. Lizneva D, Gavrilova-Jordan L, Walker W, Azziz R. Androgen excess: Investigations and management. Best Pract Res Clin Obstet Gynaecol. 2016 Nov;37:98-118.
11. Dokras A, Stener-Victorin E, Yildiz BO, Li R, Ottey S, Shah D, Epperson N, Teede H. Androgen Excess- Polycystic Ovary Syndrome Society: position statement on depression, anxiety, quality of life, and eating disorders in polycystic ovary syndrome. Fertil Steril. 2018 May;109(5):888-899.
12. Legro RS, Schlaff WD, Diamond MP et al. Total testosterone assays in women with polycystic ovary syndrome: precision and correlation with hirsutism. J Clin Endocrinol Metab. 2010 Dec;95(12):5305-13.
13. Lause M, Kamboj A, Fernandez Faith E. Dermatologic manifestations of endocrine disorders. Transl Pediatr. 2017 Oct;6(4):300-312.
14. Melibary YT. Hidradenitis suppurativa in a patient with hyperandrogenism, insulin-resistance and acanthosis nigricans (HAIR-AN syndrome). Dermatol Reports. 2018;10(1):7546.
15. Keen MA, Shah IH, Sheikh G. Cutaneous Manifestations of Polycystic Ovary Syndrome: A Cross-Sectional Clinical Study. Indian Dermatol Online J. 2017;8(2):104-110.
16. Rodgers R, Avery J, Moore V, Davies M, Azziz R, Stener-Victorin E, Moran L, Robertson S, Stepto N, Norman R, Teede HJ. Complex diseases and co-morbidities: polycystic ovary syndrome and type 2 diabetes mellitus. Endocr Connect. 2019 Feb 1. pii: EC-18-0502.R2.
17. Glueck CJ, Goldenberg N. Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics. Metabolism. 2019 Mar;92:108-120.
18. Lim S. S. et al. The effect of obesity on polycystic ovary syndrome: a systematic review and meta‐analysis //Obesity Reviews. – 2013. – Т. 14. – №. 2. – С. 95-109
19. Pasquali R, Oriolo C. Obesity and Androgens in Women. Front Horm Res. 2019;53:120-134.
20. Zheng SH, Li XL. Visceral adiposity index as a predictor of clinical severity and therapeutic outcome of PCOS. Gynecol Endocrinol. 2016;32(3):177-83.
21. Gibson-Helm M, Teede H, Dunaif A, Dokras A, et al. Delayed diagnosis and a lack of information associated with dissatisfaction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2017;102(2): 604–12
22. Dokras A, Saini S, Gibson-Helm M, Schulkin J, Cooney L, Teede H. Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome. Fertil Steril 2017;107(6): 1380–6.e1.
23. Balen AH, Morley LC, Misso M, Franks S, Legro RS, Wijeyaratne CN, et al. The management of anovulatory infertility in women with polycystic ovary syndrome: An analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update 2016;22(6):687–708.
24. Alexandraki KI, Kandaraki EA, Poulia KA, Piperi C, Papadimitriou E, Papaioannou TG. Assessment of Early Markers of Cardiovascular Risk in Polycystic Ovary Syndrome. touchREV Endocrinol. 2021 Apr;17(1):37-53.
25. Andersen M, Glintborg D. Diagnosis and follow-up of type 2 diabetes in women with PCOS: a role for OGTT? Eur J Endocrinol. 2018 Sep;179(3):D1-D14. doi: 10.1530/EJE-18-0237.
26. Anagnostis P, Tarlatzis BC, Kauffman RP. Polycystic ovarian syndrome (PCOS): Long-term metabolic consequences. Metabolism. 2018;86:33-43.
27. Nolan CJ, Prentki M. Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: Time for a conceptual framework shift. Diab Vasc Dis Res. 2019 Mar;16(2):118-127.
28. Pelanis R, Mellembakken JR, Sundström-Poromaa I, et al. The prevalence of Type 2 diabetes is not increased in normal-weight women with PCOS. Hum Reprod. 2017;32(11):2279-2286.
29. Condorelli RA, Calogero AE, Di Mauro M, La Vignera S. PCOS and diabetes mellitus: from insulin resistance to altered beta pancreatic function, a link in evolution. Gynecol Endocrinol. 2017 Sep;33(9):665-667.
30. Jeanes YM, Reeves S. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges. Nutr Res Rev. 2017 Jun;30(1):97-105.